CHRONIC LYMPHOCYTIC LEUKAEMIA REFRACTORY

This adverse event was reported 94 times

These drugs are most commonly taken by patients reporting CHRONIC LYMPHOCYTIC LEUKAEMIA REFRACTORY:

# Drug Count
0 IBRUTINIB 38
1 RITUXIMAB 31
2 VENETOCLAX 21
3 CYCLOPHOSPHAMIDE 20
4 CYCLOPHOSPHAMIDE FOR INJECTION 20
5 CYCLOPHOSPHAMIDE INJECTION, SOLUTION 20
6 FLUDARABINE PHOSPHATE 20
7 IDELALISIB 15
8 DOXORUBICIN 12
9 PREDNISONE 12
See all common drugs associated with CHRONIC LYMPHOCYTIC LEUKAEMIA REFRACTORY

CHRONIC LYMPHOCYTIC LEUKAEMIA REFRACTORY is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 CHLORAMBUCIL 9 0.0023
1 IDELALISIB 15 0.0021
2 PIRTOBRUTINIB 2 0.0020
3 FLUDARABINE PHOSPHATE 20 0.0005
4 IBRUTINIB 38 0.0005
5 GRANULOCYTE COLONY STIMULATING FACTOR 1 0.0005
6 BENDAMUSTINE HCL 7 0.0004
7 ALEMTUZUMAB 7 0.0004
8 FAMCICLOVIR 1 0.0004
9 OBINUTUZUMAB 6 0.0004
See all drugs enriched for association with CHRONIC LYMPHOCYTIC LEUKAEMIA REFRACTORY

CHRONIC LYMPHOCYTIC LEUKAEMIA REFRACTORY is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 CD52-directed Cytolytic Antibody [EPC] 7 0.0004
1 CD22-directed Immunoconjugate [EPC] 1 0.0003
2 BCL-2 Inhibitor [EPC] 21 0.0003
3 Thrombopoietin Receptor Agonist [EPC] 2 0.0001
4 Echinocandin Antifungal [EPC] 1 0.0001
5 CD20-directed Cytolytic Antibody [EPC] 32 0.0001
6 Alkylating Drug [EPC] 22 0.0001
7 Kinase Inhibitor [EPC] 40 0.0001
8 Iron Chelator [EPC] 2 0.0001
9 Non-narcotic Antitussive [EPC] 1 0.0001
See all drug classes enriched for association with CHRONIC LYMPHOCYTIC LEUKAEMIA REFRACTORY